Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Ann Oncol. 2020 Aug 13;31(11):1518–1525. doi: 10.1016/j.annonc.2020.08.2064

Table 2.

Pathologic outcomes after preoperative chemotherapy

Response Cisplatin (n = 72) Paclitaxel (n = 67) Total (n = 139)
Responder (RCB-0/1) 19 (26.4%) 15 (22.3%) 34 (24.5%)
Non-Responder (RCB-2/3 or crossover) 53 (73.6%) 52 (77.6%) 105 (75.5%)
pCR 11 (15.3%) 8 (11.9%) 19 (13.7%)
Non-pCR 61 (84.7%) 59 (88.1%) 120 (86.3%)

Abbreviations: pCR, pathologic complete response; RCB, residual cancer burden.